About this trial
This multicenter, prospective, observational study aims to develop and validate an EIT-based prognostic model for ARDS. By focusing on the pathophysiological characteristics of ARDS and the causes of ventilator-induced lung injury, the investigators intend to establish a prognostic model that reveals lung injury and heterogeneity, enabling risk stratification and guiding individualized treatment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Meet the new 2023 ARDS global definition;
Age 18-80 years
Disqualifiers
Expected death within 24 hours of screening;
Metastatic cancer (active malignancy with distant metastases);
Severe psychiatric disorders;
Pregnancy or postpartum status;
Trial population
This is a prospective, multicenter, observational cohort study that will enroll adult patients (aged 18-80 years) diagnosed with acute respiratory distress syndrome (ARDS) per the new 2023 ARDS global definition.
Trial design
Cohort
Prospective
Treatments tested in this trial
Not applicable- observational study
Other interventionNot applicable- observational study
Treatment groups
Trial outcomes
Primary outcomes
28-day mortality rate
Secondary outcomes
ICU mortality rate
60-day all-cause mortality rate
90-day all-cause mortality rate
Duration of mechanical ventilation (days)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
XiaoJing Zou,MD
Lead sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Sponsor institution